The role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults.
As the HIV pandemic enters its third decade, more sophisticated and efficacious therapies are continually being developed. This article provides an in-depth review of the first coformulated boosted protease inhibitor available on the world market, lopinavir/ritonavir (Kaletra). Included in this review is an overview of the current market place, the chemistry, pharmacokinetics, clinical efficacy and side-effect profile of lopinavir/ritonavir. In addition, an expert opinion and commentary on the clinical applications of this drug is provided.
University of Toronto, EG-219, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada. sharon.walmsley@uhn.on.ca.
Sharon
S
Walmsley
Michael D
MD
Christian
D000328:Adult; D000818:Animals; D044966:Anti-Retroviral Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
D044966:Anti-Retroviral Agents; D011744:Pyrimidinones; D061466:Lopinavir